During what has become one of the slowest IPO years in recent memory, cancer immunotherapy company Cytomed Therapeutics Ltd. debuted on Nasdaq, raising $9.65 million, while inflammatory disease firm Acelyrin Inc. filed to list its stock for a potential $100 million. Up to this point, there were only six biopharma IPOs completed this year – the fewest since 2013. Cytomed, which priced 2.4 million shares at $4 apiece, is now the seventh for 2023, and the fifth on Nasdaq. Two other IPOs have closed on Chinese markets.
Singapore’s Agency for Science, Technology and Research (A*STAR) has inked a deal with Boehringer Ingelheim GmbH to develop and commercialize targeted cancer therapies.
Singapore’s Agency for Science, Technology and Research (A*STAR) has inked a deal with Boehringer Ingelheim GmbH to develop and commercialize targeted cancer therapies.
SCG Cell Therapy Pte. Ltd. has signed a collaboration agreement with Singapore’s Agency for Science, Technology and Research (A*STAR)’s Bioprocessing Technology Institute (BTI) to advance the development of multispecific antibodies.
SCG Cell Therapy Pte. Ltd. has signed a collaboration agreement with Singapore’s Agency for Science, Technology and Research (A*STAR)’s Bioprocessing Technology Institute (BTI) to advance the development of multispecific antibodies.
SCG Cell Therapy Pte. Ltd. has acquired rights to human induced pluripotent stem cell technology from Singapore’s Agency for Science, Technology and Research (A*STAR)’s Accelerate Technologies Pte. Ltd. to support the development of natural killer (NK) cell therapies for leukemia, liver cancer, gastric cancer and other solid tumors.
SCG Cell Therapy Pte. Ltd. has acquired rights to human induced pluripotent stem cell technology from Singapore’s Agency for Science, Technology and Research (A*STAR)’s Accelerate Technologies Pte. Ltd. to support the development of natural killer (NK) cell therapies for leukemia, liver cancer, gastric cancer and other solid tumors.
Aum Biosciences Pte. Ltd., a company developing targeted cancer therapies, has closed a $27 million series A funding round. The Singapore-based company plans to use the proceeds to advance clinical development of its portfolio with immediate initiation of two phase II programs for MNK and tropomyosin receptor kinase inhibitors.
